China

The medication works as an add-on therapy alongside intranasal corticosteroids for patients whose condition fails to respond adequately to systemic corticosteroids or surgical intervention.

The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The new production hub will be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, where it will supply autologous CAR-T therapies to China and other Asian markets.

The company plans to execute this investment through two primary channels: expanding existing facilities and forging partnerships with local manufacturers.

The NMPA based its approval decision on Phase III clinical trial data published in The Lancet Diabetes & Endocrinology in June 2025.

Pfizer secured marketing rights to the GLP-1 compound ecnoglutide through a partnership with Hangzhou-based Sciwind Biosciences announced last month.

The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.

The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.